foslinanib extended release (CVM-1118 ER) / TaiRx - LARVOL DELTA

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients (clinicaltrials.gov) - P1 | N=5 | Completed | Sponsor: TaiRx, Inc. | Active, not recruiting ➔ Completed | N=15 ➔ 5

Enrollment change • Trial completion • Hematological Malignancies • Oncology • Solid Tumor

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients (clinicaltrials.gov) - P1; N=15; Active, not recruiting; Sponsor: TaiRx, Inc.; Trial primary completion date: Apr 2022 ➔ Feb 2021

Trial primary completion date • Hematological Malignancies • Oncology • Solid Tumor

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients (clinicaltrials.gov) - P1; N=15; Active, not recruiting; Sponsor: TaiRx, Inc.; Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Oncology • Solid Tumor

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients (clinicaltrials.gov) - P1; N=15; Recruiting; Sponsor: TaiRx, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients (clinicaltrials.gov) - P1; N=15; Not yet recruiting; Sponsor: TaiRx, Inc.

Clinical • New P1 trial